Table 2.
Patient and tumour characteristics for the IBC series, (n) = number of patients. ER oestrogen receptor, PgR progesterone receptor, HR hormone receptor
| Mean age (143) | 60.1 years (25.7–91.2 years) | |
| Mean sTIL score (106) | 17.63%, 95% CI 15.00–20.26% | |
| Menopausal status (142) | Premenopausal | 42 (29.4%) |
| Postmenopausal | 101 (70.6%) | |
| cN stage (142) | 0 | 6 (4.2%) |
| 1 | 53 (37.9%) | |
| 2 | 52 (37.1%) | |
| 3 | 29 (20.7%) | |
| cM stage (143) | 0 | 103 (72.0%) |
| 1 | 40 (28.0%) | |
| Pathological type (142) | Ductal | 134 (94.4%) |
| Lobular | 5 (3.5%) | |
| Mixed | 3 (2.1%) | |
| Differentiation (133) | Grade 1 | 3 (2.3%) |
| Grade 2 | 35 (26.3%) | |
| Grade 3 | 95 (71.4%) | |
| ER (141) | Negative | 67 (47.5%) |
| Positive | 74 (52.5%) | |
| PgR (141) | Negative | 88 (62.4%) |
| Positive | 53 (37.6%) | |
| HER2+ (139) | Negative | 77 (55.4%) |
| Positive | 62 (44.6%) | |
| Molecular subtype (138) | Luminal (HR+) | 76 (55.1%) |
| HER2+ (HR-HER2+) | 30 (21.7%) | |
| TN (HR-HER2−) | 32 (23.2%) | |
| sTIL (106) | < 10% | 38 (35.8%) |
| ≥ 10 to < 40% | 54 (51.9%) | |
| ≥ 40% | 13 (12.3%) | |
| PD-L1 immune cells (105) | < 1% | 60 (57.1%) |
| ≥ 1 to < 5% | 28 (26.7%) | |
| ≥ 5 to < 10% | 13 (12.4%) | |
| ≥ 10% | 4 (3.8%) | |